Search

everythinglearnresearchcommunity

for

Search:↓

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

High levels of ERK activity are key for tissue regeneration in spiny mice, and activating ERK can potentially redirect scar-forming healing towards regenerative healing in mammals.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

Different staff in a dermatology clinic understand mostly their own tasks, not the full clinic process.

Severe Hidradenitis Suppurativa increases missed and unproductive workdays.

Smoking and certain health conditions like thyroid disease may make palmoplantar pustulosis harder to treat.

Finasteride treatment lowers urine androgen and prostaglandin levels, making them potential markers for effectiveness.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Alopecia areata treatment varies, with no optimal method established yet.

Early and personalized treatment for hair loss in young people is crucial to prevent permanent damage and should include psychological support.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Hair dye ingredient PPD causes cell death and aging in human hair cells by altering microRNA levels.

Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.

New treatments and diagnostic methods for various animal skin conditions showed promising results.

Keratinocytes help heal skin wounds by interacting with immune cells and producing substances that kill pathogens.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.